Veracyte recently announced a significant, multi-year partnership with Illumina. This collaboration aims to transform some of Veracyte's high-performance molecular tests into decentralized in vitro diagnostic (IVD) tests by leveraging Illumina's NextSeq 550Dx next-generation sequencing (NGS) instrument. This strategic agreement is a pivotal element of Veracyte's broader IVD approach, which includes qPCR, and it is designed to expedite the global availability of their diagnostic tests. By incorporating well-established NGS and qPCR technologies, Veracyte seeks to enhance the diagnostic and treatment decision-making capabilities for healthcare providers and patients.

The initial tests slated for adaptation to the Illumina NextSeq 550Dx instrument include the Prosigna Breast Cancer Assay and the Percepta Nasal Swab test. The Prosigna assay is already available as an IVD test, aiding in treatment decisions for patients with early-stage breast cancer. The non-invasive Percepta Nasal Swab test is tailored to guide diagnosis and treatment decisions for individuals, including both current and former smokers, who have potentially cancerous lung nodules.

Illumina's NextSeq 550Dx instrument serves as a validated mid-throughput platform, providing access to an expanding range of clinical applications in diverse fields such as oncology, reproductive health, genetic disease testing, and more. With regulatory approvals in over 60 countries, the NextSeq 550Dx platform is widely trusted by hospitals and clinical laboratories for a comprehensive array of high-quality diagnostic tests.

Source: businesswire.com